Molecular Devices and STEMCELL Technologies Partner to Automate Organoid Culture
News related to:Molecular Devices · 1 min read
Molecular Devices and STEMCELL Technologies have partnered to streamline the creation of human intestinal organoids, a significant step in advancing research and drug discovery. The collaboration leverages the CellXpress.ai Automated Cell Culture System to automate the culture and analysis of these organoids, reducing variability and hands-on time for researchers.
The new workflow, validated on the CellXpress.ai system, combines the expertise of STEMCELL Technologies in organoid biology with the automation capabilities of Molecular Devices. This integration aims to make human-relevant organoid models more accessible and scalable, thereby accelerating research and development processes. The workflow is currently available as a downloadable protocol, providing researchers with a ready-to-implement approach to automating organoid culture.
Mary Duseau, President of Molecular Devices, emphasized the importance of this collaboration.
The validated protocol enables automated culture, monitoring, and analysis of human intestinal organoids within a standardized process on the CellXpress.ai system. Researchers can implement the validated protocol as provided or adapt it to meet specific experimental requirements, offering flexibility for a range of organoid research applications.
Dr. Allen Eaves, President and CEO of STEMCELL Technologies, highlighted the broader impact of this partnership.
The companies plan to evaluate additional organoid models and workflows for automation on the CellXpress.ai system, creating a growing portfolio of validated applications for drug discovery, disease modeling, toxicology, and translational research. This strategic collaboration reflects a shared commitment to helping researchers integrate more human-relevant models into laboratory workflows while reducing operational barriers to adoption and scale.
By combining their respective strengths, Molecular Devices and STEMCELL Technologies are poised to significantly advance the field of organoid research, making it more efficient and accessible to a wider range of scientists. This partnership marks a significant milestone in the development of human-relevant research models and paves the way for more accurate and effective drug discovery and disease modeling.